Network pharmacology analysis revealed substantial overlap between prescription targets and RA-associated genes (65-115 targets per prescription), with convergent enrichment in key inflammatory pathways, including Toll-like receptor, IL-17, and TNF signaling pathway. This evidence concerns the gene IL17A and rheumatoid arthritis.